EichorEICHOR
Location: Wollstonecraft Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Wollstonecraft

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced S
Phase 1/Phase 2 · Melanoma Institute Australia · ModernaTX, Inc. · NCT05533697Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2 · Melanoma Institute Australia · Melanoma Institute Australia · NCT06999980Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Phase 2 · Melanoma Institute Australia · Melanoma Institute Australia · NCT06288191A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · Melanoma Institute Australia · BioNTech SE · NCT07070232Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 3 · Melanoma Institute Australia · Immunocore Ltd · NCT05549297Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Phase 2 · Melanoma Institute Australia · Melanoma Institute Australia · NCT06151236The Multicentre Selective Lymphadenectomy Trial - 3
NA · Melanoma Institute Australia · Melanoma Institute Australia · NCT07049276Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Melanoma Institute Australia ( Site 3001) · Merck Sharp & Dohme LLC · NCT03486873Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · Melanoma Institute of Australia · Obsidian Therapeutics, Inc. · NCT06060613Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pemb
Phase 1/Phase 2 · Melanoma Institute Australia · Strand Therapeutics Inc. · NCT06249048IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Phase 3 · University of Sydney - Melanoma Institute Australia (MIA) - · Immunocore Ltd · NCT06112314A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0
Phase 2 · Melanoma Institute Australia ( Site 2000) · Merck Sharp & Dohme LLC · NCT06961006Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
Phase 2 · Melanoma Institute Australia · Melanoma Institute Australia · NCT06767306Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
Phase 2 · Melanoma Institute Australia · Melanoma Institute Australia · NCT03340129A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Chec
Phase 2/Phase 3 · Melanoma Institute Australia · Replimune, Inc. · NCT06581406Study of IMC-P115C in Advanced PRAME-Positive Cancers
Phase 1 · Melanoma Institute Australia · Immunocore Ltd · NCT07156136
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.